Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas
Safety and biomarker status data of the PARP7 inhibitor RBN-2397 and the IgG4 monoclonal antibody SRK-181 presented at the ESMO TAT Congress 2023
CPL304110 shows acceptable toxicity and early signs of activity in heavily pre-treated patients with advanced solid malignancies
Adding precision to dose-finding in early-phase clinical trials has become critical in the immunotherapy era, and moving away from paradigms of the past has become mandatory
Two recently published studies provide preclinical insights into ‘training’ CAR T cells that may potentially lead to more effective and less toxic immunotherapy approaches
Results of extensive genomic profiling and a Time-to-Event Continual Reassessment Method show some promise in investigating new treatments and targets in early-phase trials, despite not being ready for routine research
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
Among all the stakeholders involved, oncology societies can play a pivotal role to facilitate efficient clinical investigations
New recommendations of the MDICT Taskforce highlight the need to rethink how research studies are conducted and of multi-stakeholder collaboration
The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.